EarningsQ2 2026 Earnings Report
DE:4DN Q2 2026 EPS Results
Actual EPS-€0.61
Consensus EPS-€0.46
Beat/MissMissed by -€0.15
One Year Ago EPS-€0.64
DE:4DN Q2 2026 Revenue Results
Actual Revenue€3.21M
Expected Revenue€1.92M
Beat/MissBeat by +€1.29M
YoY Revenue Growth―
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeAfter Close
Conference CallThursday, August 6, 2026
DE:4DN Upcoming Earnings
Denali Therapeutics's next earnings date is estimated for November 11, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:4DN Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call communicated a strong, constructive start to commercialization with meaningful early revenue ($3.6M), rapid payer progress (>50% commercial lives) and platform validation via AVLAYAH, supported by a robust pro forma cash position (> $1.1B) and multiple clinical programs advancing toward 2027 readouts. Near-term challenges include variability in revenue and patient initiation timing due to weight-based dosing and infusion logistics, limited disclosed patient-level metrics, some program timing shifts (DNL593), and competitive/coverage risks. On balance, the positive commercial and platform milestones materially outweigh the near-term operational and timing uncertainties.Company Guidance
Successful First Full Commercial Quarter for AVLAYAH
AVLAYAH generated $3.6 million in net product revenue in its first full commercial quarter, marking Denali's transition to a commercial company and the first FDA-approved biologic using its transport vehicle platform.
Strong Early Launch Trajectory and Q3 Guidance
Management provided Q3 net product revenue guidance of $10 million to $12 million, implying an expected quarter-over-quarter increase from Q2 of roughly 178% to 233% (≈205% to the midpoint), driven by physician/patient demand and expanding payer coverage.
Rapid Payer Progress and Market Access
Commercial coverage policies covering more than 50% of commercial lives have been established and 14 state Medicaid programs publicly listed AVLAYAH as covered, with managed Medicaid aligning to commercial plans — favorable early access vs. analogous rare-disease launches.
Validated Transport Vehicle (ETV) Platform
AVLAYAH represents the first approved medicine developed with Denali's transport vehicle platform (ETV), providing proof-of-concept that the platform can progress from discovery to an approved CNS-penetrant biologic and enabling a broader ETV franchise opportunity across multiple lysosomal and neurodegenerative diseases.
Pipeline Advancement into Clinic (Alzheimer's and FTD-GRN)
Two Alzheimer’s programs advanced into clinical development (DNL628 tau OTV and DNL921 anti-amyloid antibody) with initial clinical biomarker/safety data expected in 2027; DNL593 (progranulin replacement for FTD-GRN) regained by Denali and given orphan drug designation.
Strong Balance Sheet and Pro Forma Cash Position
Ended Q2 with approximately $940 million in cash, cash equivalents, and marketable securities; after receiving $195 million from the sale of a PRV in July, pro forma cash and equivalents exceed $1.1 billion, providing strategic and executional flexibility.
Operational and Financial Discipline
R&D expense decreased to $97.0 million from $102.7 million year-over-year (a decrease of $5.7 million, ≈5.6%), while management kept operating expenditures broadly in line with prior year while launching AVLAYAH and advancing programs.
Commercial and Franchise Leverage Opportunity
Management highlighted that the ETV-enabled enzyme replacement franchise addresses a >$9 billion ERT market and estimated per-program opportunity of ~$500 million to >$1 billion, indicating significant potential upside from AVLAYAH commercialization experience and repeatable capabilities.
DE:4DN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed